List of Excipients in Branded Drug LOTENSIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Validus Pharmaceuticals LLC	LOTENSIN	benazepril hydrochloride	30698-449	CELLULOSE, MICROCRYSTALLINE
Validus Pharmaceuticals LLC	LOTENSIN	benazepril hydrochloride	30698-449	CROSPOVIDONE
Validus Pharmaceuticals LLC	LOTENSIN	benazepril hydrochloride	30698-449	FERRIC OXIDE RED
Validus Pharmaceuticals LLC	LOTENSIN	benazepril hydrochloride	30698-449	HYDROGENATED CASTOR OIL
Validus Pharmaceuticals LLC	LOTENSIN	benazepril hydrochloride	30698-449	HYPROMELLOSES

Lotensin (Benazepril) Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Lotensin is the branded tablet formulation of benazepril hydrochloride, an angiotensin-converting enzyme inhibitor approved for hypertension. Its core commercial opportunity is no longer branded small-molecule exclusivity. The opportunity is in low-cost generic manufacturing, differentiated oral dosage forms, excipient substitution, pediatric or geriatric delivery, and fixed-dose cardiovascular products. Lotensin has no biosimilar pathway because benazepril is a chemically synthesized small molecule.

What is Lotensin and which excipients are used?

Lotensin contains benazepril hydrochloride in immediate-release tablets at 5 mg, 10 mg, 20 mg, and 40 mg strengths. Benazepril is a prodrug converted to benazeprilat, the active angiotensin-converting enzyme inhibitor metabolite. The drug is administered once daily for hypertension, with or without food, according to product labeling. [1]

The branded tablet label identifies a conventional compressed-tablet excipient system that includes the following materials:

Excipient or excipient class	Likely formulation function
Lactose monohydrate	Diluent and tablet mass
Microcrystalline cellulose	Diluent, compression aid, disintegration support
Crospovidone	Superdisintegrant
Povidone	Binder
Hydroxypropyl cellulose or hypromellose	Binder, film-forming or viscosity control
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and moisture-management aid
Talc	Anti-adherent and processing aid
Polyethylene glycol	Film-coating plasticizer
Titanium dioxide	Opacifier and colorant
Iron oxide	Strength-specific tablet colorant
Polysorbate 80, where used in the coating system	Wetting or coating aid

The exact inactive-ingredient composition can vary by strength, market, manufacturer, and approved product presentation. Generic applicants are not required to copy the Lotensin excipient system. They must demonstrate pharmaceutical equivalence and bioequivalence under the applicable abbreviated new drug application pathway. [2]

What technical attributes matter in a benazepril tablet?

The main development variables are blend uniformity, tablet disintegration, dissolution, chemical stability, and control of moisture exposure. The 5 mg strength presents the greatest content-uniformity challenge because the active ingredient represents a small fraction of tablet mass.

A practical generic formulation normally uses:

• Lactose, microcrystalline cellulose, or a lactose-free substitute as the principal diluent.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Povidone or hydroxypropyl cellulose as the binder.
• Magnesium stearate at a controlled concentration to avoid impaired dissolution.
• Colloidal silicon dioxide to improve flow in direct compression or dry granulation.
• Film coating to support product identification, handling, and moisture protection.

The excipient system should be selected against the active ingredient’s degradation profile rather than copied from the originator. The key screening work includes moisture sorption, blend segregation, lubricant sensitivity, accelerated stability, photostability, and dissolution across pH conditions.

What is the Orange Book status of Lotensin?

Lotensin is an established small-molecule product with generic competition. The relevant regulatory pathway is an ANDA for benazepril hydrochloride tablets, not a biosimilar application. FDA Orange Book records determine the current reference-listed drug, therapeutic-equivalence codes, patents, and exclusivity status. [2]

Regulatory issue	Lotensin position
Active ingredient	Benazepril hydrochloride
Dosage form	Immediate-release tablet
Reference product	Lotensin tablets
FDA pathway for generics	ANDA under section 505(j)
Biosimilar pathway	Not applicable
Orange Book relevance	Reference product, listed patents, exclusivity, therapeutic equivalence
Current commercial model	Generic commodity market with formulation differentiation opportunities

The original Lotensin regulatory exclusivity and principal composition-of-matter protection have expired. The product is therefore exposed to conventional generic substitution. Any current market exclusivity would need to be confirmed against the live Orange Book record for the applicable reference product and strength.

When did Lotensin lose exclusivity?

Lotensin lost practical branded exclusivity years ago. Benazepril hydrochloride tablets are widely available as generic products, and the core commercial barriers are manufacturing economics, regulatory compliance, distribution access, and payer contracting rather than basic patent protection.

The core patent estate was directed to benazepril and related ACE-inhibitor chemistry. Those rights are expired or no longer commercially blocking for ordinary benazepril hydrochloride tablets. Later patents, if any, would have been more likely to cover specific combinations, formulations, manufacturing processes, or use claims rather than the basic active ingredient.

Exclusivity category	Commercial assessment
Composition of matter	Expired
Original product patent protection	Expired
FDA new-drug exclusivity	Expired
Basic immediate-release tablet protection	Not a current barrier
Pediatric exclusivity	No meaningful current barrier for ordinary generic entry
Formulation or combination patents	Must be assessed product by product
ANDA litigation risk	Generally low for ordinary benazepril tablets, subject to current Orange Book records

A generic applicant can face Paragraph IV litigation only if an Orange Book-listed patent remains relevant to the proposed product or method of use. For an ordinary benazepril tablet, the principal risk is limited compared with newer branded products. The commercial issue is usually whether the applicant can obtain an economically viable ANDA approval and compete in a crowded market.

What excipient strategies can differentiate a generic benazepril product?

The strongest opportunity is not a cosmetic excipient change. It is a formulation that solves a defined patient, manufacturing, or procurement problem while preserving a straightforward regulatory pathway.

Lactose-free formulation

A lactose-free product could target patients with lactose intolerance, hospitals seeking excipient standardization, and markets where lactose-free labeling has commercial value. Suitable alternatives include microcrystalline cellulose, mannitol, dibasic calcium phosphate, pregelatinized starch, and selected co-processed excipients.

The development tradeoff is tablet size. Replacing lactose may increase tablet weight or alter compactability. Calcium phosphate can improve hardness but may change disintegration and dissolution behavior. Mannitol can improve mouthfeel but may raise material cost.

Low-cost direct-compression formulation

Direct compression can reduce processing steps, solvent use, and manufacturing overhead. A blend of microcrystalline cellulose, spray-dried lactose, crospovidone, and colloidal silicon dioxide may support a robust process.

The main risks are segregation at the 5 mg strength, sensitivity to lubricant overmixing, and variability in tablet weight. Content-uniformity controls are central to the development strategy.

Moisture-protected formulation

A moisture-protected tablet may improve shelf life in hot and humid regions. Options include:

• Lower-moisture excipient grades.
• High-barrier blister packaging.
• Desiccant-containing bottles.
• Protective film coatings.
• Tighter water-activity specifications.
• Dry granulation instead of aqueous processing.

Packaging is often more commercially efficient than a complex reformulation. A generic manufacturer can preserve the standard excipient platform while improving stability through blister selection and container-closure engineering.

Geriatric and dysphagia-oriented formulation

Hypertension is prevalent in older adults, creating a potential opportunity for:

• Smaller tablets.
• Scored tablets where supported by dose uniformity.
• Easier-to-swallow tablet geometry.
• Orally disintegrating tablets.
• Sprinkle capsules or multiparticulate systems.
• Liquid formulations.

A smaller tablet is the lowest-risk option. An orally disintegrating tablet would require new performance development, including in-mouth disintegration, taste evaluation, mechanical strength, packaging, and bioequivalence. Benazepril’s bitter or medicinal taste could require taste masking.

Pediatric liquid formulation

Benazepril is used in pediatric hypertension in clinical practice, but an approved commercial oral liquid may offer a differentiated product opportunity where an age-appropriate formulation is not broadly available. Potential systems include:

• A ready-to-use aqueous solution.
• A powder for reconstitution.
• A suspension.
• A pharmacy-compounded formulation converted into a standardized commercial product.

A liquid product would face stability, preservative, microbial, dosing-device, and palatability requirements. A 505(b)(2) strategy could be relevant if the product relies on published literature or an existing FDA finding rather than a conventional ANDA presentation. The route would depend on the exact dosage form and reference product relationship.

What formulations are protected by Lotensin or benazepril patents?

The original product’s commercial protection was centered on benazepril chemistry and the branded tablet. Current opportunities are more likely to involve new product claims than enforcement of the original Lotensin estate.

Potentially protectable subject matter includes:

Formulation area	Potential claim focus
Oral solution	Concentration, pH, preservative system, stability
Suspension	Particle size, suspending agent, redispersibility
Orally disintegrating tablet	Disintegration time, taste masking, friability
Modified release	Release profile and dosing interval
Combination tablet	Benazepril with amlodipine or another cardiovascular agent
Manufacturing process	Granulation, drying, blending, compression, coating
Packaging	Moisture-barrier configuration and stability performance
Patient population	Defined method-of-use claims, if legally supportable

A new excipient alone is rarely a strong patent position. Stronger protection usually requires a measurable technical result, such as improved chemical stability, reduced degradation, improved dissolution, better content uniformity, or a clinically relevant administration advantage.

How does Lotensin compare with Lotrel and other ACE inhibitors?

Lotensin competes with generic benazepril, lisinopril, enalapril, ramipril, quinapril where available, and fixed-dose combinations. Lotrel combines amlodipine and benazepril and has a broader formulation opportunity because it addresses two antihypertensive mechanisms in one product.

Product	Active ingredient or ingredients	Formulation opportunity	Competitive position
Lotensin	Benazepril hydrochloride	Lactose-free, liquid, ODT, low-cost generic	Mature generic market
Lotrel	Amlodipine/benazepril	Fixed-dose combinations, strength optimization	Combination-product competition
Lisinopril tablets	Lisinopril	Low-cost tablets, oral solution	High-volume generic benchmark
Enalapril tablets	Enalapril	Pediatric liquid and standard tablets	Established generic market
Ramipril capsules	Ramipril	Capsule and dose flexibility	More differentiated dosage form
Benazepril/amlodipine alternatives	Combination therapy	Hospital and adherence positioning	Potentially higher value per prescription

Benazepril may have a commercial niche where prescribers prefer it for patients already controlled on the molecule or where combination therapy with amlodipine is clinically appropriate. It is unlikely to support premium pricing as a conventional tablet without a differentiated delivery or supply proposition.

What generic entry risks exist for benazepril?

Generic entry risk is high because the product has an expired core patent estate, a familiar tablet dosage form, and multiple potential suppliers. The main risks for a new entrant are commercial rather than legal.

Market risks

• Low average selling prices.
• Pharmacy benefit manager pressure.
• Formulary substitution.
• Limited brand loyalty.
• High customer concentration.
• Price erosion after additional ANDA approvals.
• Inventory and shortage exposure if production is concentrated.

Regulatory risks

• Failure of dissolution similarity.
• Content-uniformity problems at the 5 mg strength.
• Inadequate stability in high-humidity markets.
• Excipient incompatibility.
• Manufacturing-site deficiencies.
• Incomplete justification for a nonstandard dosage form.
• Labeling differences that prevent therapeutic-equivalence substitution.

Technical risks

Benazepril hydrochloride development should specifically assess hydrolysis, oxidation, moisture uptake, blend segregation, and coating performance. The product has a low-dose strength range, so a formulation that performs well at 40 mg may not transfer directly to 5 mg.

Are there Paragraph IV challenges or litigation affecting Lotensin?

The commercial history of benazepril includes the type of generic competition associated with an expired small-molecule product. Current Paragraph IV risk should be assessed through the active Orange Book patent listing and FDA approval records rather than historical brand litigation.

For a new conventional ANDA, the likely legal profile is:

Issue	Assessment
Composition patent challenge	Low current relevance because original protection has expired
Formulation patent challenge	Product-specific
Method-of-use patent challenge	Product-specific and dependent on proposed labeling
Declaratory judgment risk	Low for a conventional generic with no listed patent barrier
Patent settlement exposure	Unlikely to be a central barrier for ordinary tablets
Litigation cost	More likely driven by commercial disputes, quality claims, or supply contracts

No current litigation conclusion should be drawn from historical Lotensin litigation without checking the relevant federal docket and Orange Book entries for the specific product and applicant.

What licensing deals could support a Lotensin opportunity?

Licensing value is more likely to arise from delivery technology, regional distribution, manufacturing capacity, or a fixed-dose combination than from the benazepril active ingredient.

Potential transaction structures include:

1. Regional licensing of a benazepril oral liquid or orally disintegrating tablet.
2. Contract manufacturing with a supplier holding validated low-dose compression capacity.
3. Co-development of benazepril/amlodipine or another cardiovascular combination.
4. Acquisition of an ANDA with approved manufacturing sites.
5. Supply agreements for lactose-free, moisture-protected, or hospital-packaged tablets.
6. In-licensing of a taste-masking or multiparticulate platform.

A license should be evaluated against the product’s expected net price, annual volume, approval costs, stability package, and substitution status. A technically differentiated formulation has limited value if payers treat it as interchangeable with a low-cost standard tablet.

What is the revenue exposure and commercial opportunity?

Lotensin itself is unlikely to provide substantial branded revenue exposure because generic benazepril has replaced the original brand in routine dispensing. The opportunity is volume-based.

Opportunity	Revenue profile	Margin potential	Development burden
Standard 5/10/20/40 mg tablets	High volume, low price	Low	Low to moderate
Lactose-free tablets	Moderate niche volume	Moderate	Moderate
Moisture-protected regional product	Moderate	Moderate	Moderate
Oral liquid	Lower volume, higher unit value	Moderate to high	High
ODT or dysphagia product	Niche	Potentially high	High
Benazepril/amlodipine combination	Moderate to high	Moderate	Moderate to high
Hospital unit-dose packaging	Contract-dependent	Moderate	Low to moderate

The most defensible commercial strategy is a two-tier portfolio: a low-cost standard tablet for volume and a differentiated dosage form for higher margin. A stand-alone premium tablet without clinical, adherence, packaging, or supply-chain differentiation is unlikely to sustain pricing.

How strong is the benazepril patent estate?

The patent estate is weak for ordinary benazepril hydrochloride tablets because the original composition and product protection have expired. New patent value would need to come from a specific, enforceable improvement.

Patent category	Strength for new commercial entry
Original benazepril composition	Very weak or expired
Standard immediate-release tablet	Weak
New excipient combination without unexpected result	Weak
Oral liquid with stability advantage	Moderate
ODT with validated technical performance	Moderate
Fixed-dose combination	Moderate, subject to prior art
Manufacturing process with measurable advantage	Moderate
Packaging and moisture protection	Narrow but potentially useful
Method of use	Dependent on claim scope and prior art

Geographic coverage is also limited by the age of the product. U.S. patent protection is not the only relevant issue. A company commercializing globally must review national registrations, local data exclusivity, trademark rights, manufacturing approvals, and product-specific patent records in Europe, Japan, China, Canada, and other target markets.

Key Takeaways

• Lotensin is benazepril hydrochloride in immediate-release tablet form.
• The original composition and branded exclusivity have expired.
• Standard generic tablets face high substitution and price pressure.
• The most useful excipient strategies are lactose-free design, moisture protection, low-dose content-uniformity control, and geriatric-friendly delivery.
• Oral liquids and orally disintegrating tablets offer higher differentiation but require greater stability, taste, packaging, and regulatory work.
• No biosimilar pathway applies because benazepril is a synthetic small molecule.
• Paragraph IV risk is limited for conventional tablets unless a current Orange Book-listed patent is identified.
• A benazepril/amlodipine combination may offer more commercial differentiation than a stand-alone benazepril tablet.
• New patent value would need to arise from a specific formulation, process, combination, or delivery improvement.
• The strongest business model is a low-cost generic base product paired with a targeted higher-value formulation.

FAQs

Is Lotensin still protected by a patent?

The original Lotensin and benazepril composition protections are expired. Any current patent issue would relate to a specific formulation, combination, manufacturing process, or method of use.

Can a generic manufacturer copy Lotensin’s excipients?

A generic manufacturer can use a different excipient system if it meets applicable quality, safety, pharmaceutical-equivalence, bioequivalence, stability, and labeling requirements.

Is there a commercial opportunity for a benazepril oral solution?

Yes. A standardized oral solution or suspension could address pediatric, geriatric, and dysphagia-related needs, but it would require significant work on stability, taste, preservation, dosing accuracy, and regulatory positioning.

Does benazepril have biosimilar competition?

No. Benazepril is a chemically synthesized small molecule. Competitors enter through ANDAs or, for certain differentiated products, potentially through a 505(b)(2) application.

Which excipient substitution is most commercially attractive?

A lactose-free, moisture-protected tablet is likely to offer the most practical balance between differentiation, manufacturing feasibility, and regulatory burden. An oral liquid or ODT could command more value but carries materially higher development risk.

References

1. Novartis Pharmaceuticals Corporation. (2016). Lotensin (benazepril hydrochloride) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry.

4. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides and other products. Guidance for industry.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.